Skip Nav Destination
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction
Issue Archive
December 23 2025
In Progress
Volume 9 Issue 24 | Blood Advances | American Society of Hematology
THROMBOSIS AND HEMOSTASIS
RESEARCH LETTER
Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma
Maria Teresa Bilotta,Antonio Giovanni Solimando,Vanessa Desantis,Lucia Di Marzo,Andrea Sabatini,Sergio Forcelloni,Alessandro Andriano,Arcangelo Morizio,Antonella Argentiero,Roberto Ria,Linda Quatrini,Lorenzo Moretta,Paola Vacca,Nicola Tumino
REVIEW ARTICLE
Lymphoid Neoplasia
CLINICAL TRIALS AND OBSERVATIONS
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study
Clinical Trials & Observations
Olivier Tournilhac,Kamal Bouabdallah,Solène Lecolant,Maya Hacini,Kamel Laribi,Sébastien Bailly,Thibaut Belmondo,Marie Maerevoet,Loic Ysebaert,Stéphanie Guidez,Steven Le Gouill,Christophe Bonnet,Marc André,Jehan Dupuis,Catherine Thieblemont,Emmanuel Bachy,Nicolas Daguindau,Franck Morschhauser,Sabine Tricot,Charline Moulin,Anne Banos,Roch Houot,Adrien Chauchet,Emmanuel Gyan,Guillaume Cartron,Hassan Farhat,Vincent Camus,Bernard Drenou,Hacene Zerazhi,David Sibon,Emmanuelle Nicolas-Virelizier,Caroline Delette,Sylvia Snauwaert,Sarah Bailly,Richard Delarue,Sylvain Carras,Albane Ledoux-Pilon,Marie-Cécile Parrens,Samuel Griolet,Philippe Gaulard,Marie-Hélène Delfau-Larue,Laurence de Leval,Gandhi Laurent Damaj
TRANSPLANTATION
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction
Clinical Trials & Observations
Jeremy D. Rubinstein,Giang Pham,Anusha Sridharan,Ruby Khoury,YunZu M. Wang,Zahra Hudda,Jamie Wilhelm,Daniel A. Lichtenstein,Daria Heyenbruch,Jose A. Cancelas,Stella M. Davies,Carolyn Lutzko,Michael S. Grimley
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies
Michael Loschi,Marie-Charlotte Villy,Jacques-Emmanuel Galimard,Marie-Mathilde Auboiroux,Nathalie Gachard,Alexandre Perani,Matthieu Duchmann,Laetitia Largeaud,Stéphanie Nguyen,Flore Sicre de Fontbrune,Marie Robin,Ibrahim Yakoub-Agha,Etienne Daguindau,Sylvain Chantepie,Amandine Charbonnier,Delphine Lebon,Sébastien Maury,Hélène Labussiere-Wallet,Anne Huynh,Edouard Forcade,Cristina Castilla-Llorente,Thomas Cluzeau,Lionel Adès,Maud D’aveni,Raynier Devillier,Natacha Maillard,Sami Benachour,Hervé Dombret,Christian Récher,Arnaud Pigneux,Emmanuelle Clappier,Eric Delabesse,Nicolas Duployez,Pascal Turlure,Régis Peffault de Latour,Marie Sébert
MYELOID NEOPLASIA
ADVANCES VIEWPOINT
Inside Blood Advances
Red Cells, Iron, and Erythropoiesis
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe
Elise R. A. Pennings,Anne M. Spanjaart,Frederick W. Thielen,Simone Oerlemans,Anna Fleischer,Carmen Sanges,Maria Gomes Da Silva,Yolanda Cabrerizo,Pacôme Lecot,Lutgart Roux-Opstaele,Caroline Dreuillet,Eglys Gonzalez-Marcano,Olga Millán,Ulrich Jaeger,Julio Delgado,Maik Luu,Barbara Huber,Margot Lorrain,Mariana Pina,Andreas Kremer,Natacha Bolaños,Solène Clavreul,Samantha Nier,Roberto D. K. Liu,Birgit I. Lissenberg-Witte,Sébastien Anguille,Marie Robin,Emma C. Morris,Anna Sureda,Marie Préau,Myriam Pannard,Geertruida H. De Bock,Scott S. Wagers,Hélène Negre,Delphine Maucort-Boulch,Michael Hudecek,Carin A. Uyl-de Groot,Marie José Kersten
Advertisement intended for health care professionals
Advertisement intended for health care professionals










